CardiAQ Valve wins FDA nod for mitral valve trial

CardiAQ Valve Technologies says the FDA granted investigation device exemption for an early feasibility trial of its transcatheter mitral valve implant.

CardiAQ Valve Technologies today said it won a nod from the FDA for an early feasibility trial of its 2nd-generation transcatheter mitral valve implant.

CardiAQ Valve Technologies, Food & Drug Administration (FDA)

News Well, Clinical Trials, Investigational Device Exemption (IDE), Regulatory/Compliance, Replacement Heart Valves

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1z2Gu5d